{"groups":[{"description":"Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nTrebananib: Given IV","id":"FG000","title":"Treatment (Trebananib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"GOG 0229L accrued 35 patients from June 2011 to August 2012. 32 of these patients were eligible."}